Literature DB >> 12829917

Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients.

Edward Cole1, Nava Maham, Carl Cardella, Daniel Cattran, Stanley Fenton, Jayne Hamel, Catherine O'Grady, Robert Smith.   

Abstract

BACKGROUND: Cyclosporine monitoring using the 2-hr postdose sample, C2, has been shown to have advantages in monitoring de novo renal transplant recipients. The purpose of this study was to assess cyclosporine exposure, using C2, in stable renal transplant patients previously monitored by C0 to determine the effect of dose reduction on patients with C2 more than 10% above target and the course of those with C2 at and more than 10% below target, whose dose was not modified.
METHODS: One hundred and seventy-five patients, three or more months after transplantation, had C2 assessed. The relationship of C2 to C0 and of both to renal function was analyzed by linear regression. Blood pressure, serum creatinine level, and lipids were followed for a mean of 15+/-2.6 months.
RESULTS: Eighty-five patients had values more than 10% above target, 42 were within 10% of target, and 48 were more than 10% below target. Cyclosporine dose was reduced in all patients above target. In this group, serum creatinine level was stable overall, but fell significantly in 46 (54%) of 85 from 153+/-55 to 132+/-49 microM. Blood pressure also fell in that group from 135/82 to 131/77. Serum creatinine level was stable in the remaining two groups of patients.
CONCLUSIONS: These data suggest that dose reduction in many overexposed patients leads to improvements in renal function and blood pressure. Further study is required to confirm the long-term benefits of this strategy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829917     DOI: 10.1097/01.TP.0000068868.01424.61

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients.

Authors:  Zheng Jiao; Xiao-jin Shi; Zhong-dong Li; Ming-kang Zhong
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

Review 2.  Therapeutic drug monitoring in pediatric renal transplantation.

Authors:  Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2014-04-25       Impact factor: 3.714

3.  Efficacy, Side Effects, and Monitoring of Oral Cyclosporine in Interstitial Cystitis-Bladder Pain Syndrome.

Authors:  Iryna M Crescenze; Barbara Tucky; Jianbo Li; Courtenay Moore; Daniel A Shoskes
Journal:  Urology       Date:  2017-05-18       Impact factor: 2.649

4.  [Cyclosporine monitoring in patients with chronic uveitis].

Authors:  S Schmidt; U Pleyer
Journal:  Ophthalmologe       Date:  2005-04       Impact factor: 1.059

5.  Advantages of cyclosporin A using 2-h levels in pediatric kidney transplantation.

Authors:  Lars Pape; Jochen H H Ehrich; Gisela Offner
Journal:  Pediatr Nephrol       Date:  2004-07-10       Impact factor: 3.714

6.  [Significance of cyclosporin A absorption for effective immunomodulatory therapy after high-risk keratoplasty].

Authors:  N Bailly; I Dunewa; P Schlattmann; P W Rieck
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

7.  Cyclosporine therapeutic monitoring with C(MAX) in kidney transplant recipients: racial considerations.

Authors:  Amgad E El-Agroudy; Amani M Ismail; Mohamed Nassar; Mohamed A Ghoneim
Journal:  Clin Exp Nephrol       Date:  2008-12-16       Impact factor: 2.801

8.  Two-hour post-dose cyclosporin A levels in adolescent renal transplant recipients in the late post-transplant period.

Authors:  Salih Kavukçu; Alper Soylu; Mehmet Türkmen; Belde Kasap; Mukaddes Gümüştekin; Hüseyin Gülay
Journal:  Pediatr Nephrol       Date:  2004-03-31       Impact factor: 3.714

9.  Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial.

Authors:  Kazumoto Iijima; Mayumi Sako; Mari Saito Oba; Shuichi Ito; Hiroshi Hataya; Ryojiro Tanaka; Yoko Ohwada; Koichi Kamei; Kenji Ishikura; Nahoko Yata; Kandai Nozu; Masataka Honda; Hidefumi Nakamura; Michio Nagata; Yasuo Ohashi; Koichi Nakanishi; Norishige Yoshikawa
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 8.237

10.  Change of Cyclosporine Absorption over the Time after Kidney Transplantation.

Authors:  Behzad Einollahi; Mojtaba Teimoori; Zohreh Rostami
Journal:  Nephrourol Mon       Date:  2012-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.